Despite minimal growth in MRSA treatment space to 2024, opportunities will exist for new entrants

Opportunities within the market are rife, even with its ostensible homogeneity


(Photo Courtesy:

The Methicillin-Resistant Staphylococcus Aureus (MRSA) treatment market will experience very limited growth over the next decade, rising from $1.4 billion in 2014 to $1.45 billion by 2024, according to research and consulting firm GlobalData.

The company's latest report states that the $50 million increase, which will occur across the seven major markets (7MM) of the US, Japan, the UK, France, Italy, Spain, and Germany, represents a very modest Compound Annual Growth Rate (CAGR) of 0.4%.

This minimal increase will be largely the product of a treatment space dominated by three primary agents, namely vancomycin, Zyvox (linezolid), and Cubicin (daptomycin).

However, Dr Christopher J Pace, GlobalData's Director of Infectious Diseases, emphasizes that opportunities within the market are rife, even with its ostensible homogeneity.

Dr Pace says: "Despite its status as the most commonly prescribed antibiotic for MRSA infections, vancomycin has a substantial number of clinical drawbacks.


Previous 1 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

Union Budget

Has Union budget 2017 addressed all requirements of healthcare industry?

Send this article by email